4Troui A, Colevas A I), Setser A, et al. Development of a comprehensive grading system for the advense effects Of can cer treatment[J]. Semin Radiat Oncol, 2003, 13(3): 176. 被引量：1
5Okur Fv, Oguz A, Karadeniz C, et al. Refractoriness to fit- uximad monotherapy in a child with relapsed/refarctory Buiitt non-Hodgkin Lymlphoma [J]. Pediatr. Hematolcol, 2006, 23(1): 25. 被引量：1
6Imamura T, Yoshihara T, Morimoto A, et al. Successful autologous peripheral blood siem ceil transplantation with ritux imab administration for pediatric diffuse large B-cell lyre phoma[J]. Pediatr Hernatol Oncol, 2006, 23( 1 ) : 19. 被引量：1
7Plosker G L, Figgitt D P. Rituximab: a review of its use in non-Hodgkin' s lymphoma and chronic lymphocytic leukaemia[J]. Drugs, 2003, 63(8): 803. 被引量：1
8Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classi- fication of lymphoid neoplasms and beyond: evolving concepts and practical applications [ J ]. Blood, 2011,117 ( 19 ) : 5019 5032. 被引量：1
9Jaffe ES, Harris NL, Stein H, et al. Classification of lymphoid ne- oplasms:the microscope as a tool for disease discovery [J~. Blood ,2008,112 ( 12 ) :4384 ~ 4399. 被引量：1
10Piris Miguel A, Arribas Alberto, Mollejo Manuela. Marginal zone lymphoma [ J]. Seminars in diagnostic pathology,2011,28 (2) : 135 ~ 145. 被引量：1
